uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients
Show others and affiliations
2011 (English)In: American Journal of Transplantation, ISSN 1600-6135, E-ISSN 1600-6143, Vol. 11, no 7, 1444-1455 p.Article in journal (Refereed) Published
Abstract [en]

Sotrastaurin, a selective protein-kinase-C inhibitor, blocks early T-cell activation through a calcineurin-independent mechanism. In this study, de novo renal transplant recipients with immediate graft function were randomized 1: 2 to tacrolimus (control, n = 44) or sotrastaurin (300 mg b.i.d.; n = 81). All patients received basiliximab, mycophenolic acid (MPA) and steroids. The primary endpoint was the composite of treated biopsy-proven acute rejection (BPAR), graft loss, death or lost to follow-up at month 3. The main safety assessment was estimated glomerular filtration rate (eGFR); modification of diet in renal disease (MDRD) at month 3. Composite efficacy failure at month 3 was higher for the sotrastaurin versus control regimen (25.7% vs. 4.5%, p = 0.001), driven by higher BPAR rates (23.6% vs. 4.5%, p = 0.003), which led to early study termination. Median (+/- standard deviation [SD]) eGFR was higher for sotrastaurin versus control at all timepoints from day 7 (month 3: 59.0 +/- 22.3 vs. 49.5 +/- 17.7 mL/min/1.73 m(2), p = 0.006). The most common adverse events were gastrointestinal disorders (control: 63.6%; sotrastaurin: 88.9%) which led to study-medication discontinuation in two sotrastaurin patients. This study demonstrated a lower degree of efficacy but better renal function with the calcineurin-inhibitor-free regimen of sotrastaurin+MPA versus the tacrolimus-based control. Ongoing studies are evaluating alternative sotrastaurin regimens.

Place, publisher, year, edition, pages
2011. Vol. 11, no 7, 1444-1455 p.
Keyword [en]
Allotransplantation, calcineurin inhibitor toxicity, drug development, efficacy, immunosuppression, mycophenolic acid, renal function, safety, tacrolimus, T-cell activation
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-156263DOI: 10.1111/j.1600-6143.2011.03538.xISI: 000292264000016OAI: oai:DiVA.org:uu-156263DiVA: diva2:431236
Available from: 2011-07-18 Created: 2011-07-18 Last updated: 2011-07-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Transplantation Surgery
In the same journal
American Journal of Transplantation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 158 hits
ReferencesLink to record
Permanent link

Direct link